Management

Jamal El-Mosleh
Jamal El-Mosleh
CEO

Jamal El-Mosleh, born in 1981, has a Master of Science (M.Sc.) in Industrial Engineering and Management from Chalmers University of Technology and a Master in Innovation and Entrepreneurship from Chalmers School of Entrepreneurship (Bio track), Gothenburg, Sweden.

Jamal most recently held position as the CEO of the biotech company Immunicum AB (2007-2017), where he took the company’s leading candidate from idea to an extensive international clinical program for multiple oncology indications. Jamal is member of the board at Elypta AB (cancer diagnostic). Jamal has been the CEO of Annexin Pharmaceuticals AB since October 2017.

Shareholdings in the Company: 211 548 shares and 486 300 share option rights series TO3

Henrik Palm
Henrik Palm
Chief Financial Officer

Henrik Palm, born in 1958, comes from the position of CFO of Karo Pharma AB. He has a degree in economics from the University of Gothenburg. Henrik has many years of experience as Business Controller within the Ericsson Group and as CFO for ElektronikGruppen BK AB and Feelgood Svenska AB.

Anna Frostegård
Anna Frostegård
MD, PhD, Licensed Physician, Chief Scientific and Medical Officer

Anna Frostegård, born in 1973, is a globally educated Licensed Physician who earned her Doctor of Medicine degree summa cum laude and earned her Doctor of Philosophy degree in Experimental Medicine from Karolinska Instututet. Anna has served as an Assistant Professor at the Unit of Immunology and Chronic Disease and has more than 10 years’ experience in translating academic discoveries into the development of biological drugs. Anna is one of the inventors and co-founder of Annexin Pharmaceuticals. Anna is an expert in Annexin A5, vascular inflammation and cardiovascular diseases. Anna has been serving as Chief Scientific and Medical Officer (CSO/CMO) of Annexin Pharmaceuticals since 2016.

Shareholdings in the Company: 468,324 shares indirectly through Frostskog AB and Medirista AB (which own 342,324 and 126,000 shares of Annexin respectively) and 309 464 share options rights series TO3

Susan Suchdev
Susan Suchdev
Chief Operating Officer

Susan Suchdev, born in 1972, comes from the position as COO and member of the management team at Klaria. Susan, who has an M.Sc. from Karolinska Institutet in Stockholm, has previously had a long career with project management roles in clinical development projects, including Pfizer, TFS Trial Form Support and Nestlé Health Science.